CD274 and non-small cell lung carcinoma: There is an unmet clinical need to identify early-stage NSCLC patients who are likely to develop recurrence and to predict the clinical benefits of chemotherapy, with or without subsequent immunotherapy depending on their PD-L1 expression levels.